Cardinal Health NYSE: CAH
Cardinal Health has a wide range of professional medical products from anesthesia-related equipment to laboratory products down to consumables such as gloves
Name | Cardinal Health |
Ticker | CAH |
Exchange | NYSE |
Sector | Health Care |
Industry | Medical Consumables & Intermediates |
Price
52W Low/High |
60.82
45.25 / 62.46 |
Momentum | Weak Up |
Market cap | 18 B |
1Y Total Return |
24.38%
Below Average |
1Y Volatility |
33.66%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cardinal Health has a wide range of professional medical products from anesthesia-related equipment to laboratory products down to consumables such as gloves
Details
Ticker | CAH |
Name | Cardinal Health |
ISIN | US14149Y1082 |
CUSIP | 14149Y108 |
Exchange | NYSE |
Sector | Health Care |
Industry | Medical Consumables & Intermediates |
Country | USA |
Currency | U.S. Dollar |
Share as of 4/14/21
Close Price | 60.82 |
52W Low/High | 45.25 / 62.46 |
Market cap | 18 B |
1Y Total Return |
24.38%
Below Average |
1Y Volatility |
33.66%
Less Risk |
Beta | 1.22 |
PE (trailing) |
12.97
Low |
12M Dividends | 1.939 |
Last Dividend Date | 12/31/20 |
Dividend Yield | 3.19% |
Fin. Strength
Net Profit Margin | 0.9% |
Cash from Op. / Cur. Liabilities | 0.13 |
Diluted Earnings / Share | 4.69 |
ROE | 93.1% |
ROIC | 7.8% |
Price / Revenue | 0.1 |
Price / Book | 9.1 |
Price / CF | 5.3 |
Current Ratio | 1.2 |
Cur.Liabilities / Tot.Liabilities | 0.6 |
Financial Leverage | 3.42 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
156,452
|
149,657
|
141,935
|
132,614
|
127,235
|
112,423
|
|
Gross Profit |
6,966
|
6,831
|
7,045
|
6,884
|
6,547
|
6,105
|
|
R&D |
0
|
0
|
0
|
0
|
0
|
0
|
|
EBITDA |
2,107
|
-3,221
|
1,743
|
2,606
|
3,019
|
2,868
|
|
Operating Income |
691
|
-4,181
|
735
|
1,716
|
2,349
|
2,329
|
|
Net Income exc. Extra |
1,382
|
-
|
-
|
1,823
|
1,351
|
1,369
|
|
per Share | |||||||
Diluted avg Shares |
295
|
294
|
300
|
316
|
319
|
332
|
|
EPS exc. Extra |
4.69
|
-14.26
|
-0.01
|
5.75
|
4.17
|
4.10
|
|
Dividend |
1.94
|
1.92
|
1.89
|
1.84
|
1.73
|
1.50
|
|
Div. Yield (an.) |
3.62%
|
3.80%
|
4.24%
|
2.99%
|
2.41%
|
1.68%
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
44,719
|
41,042
|
40,462
|
42,905
|
35,021
|
33,507
|
|
Cash, Eq & Invt ShortTerm |
3,737
|
1,659
|
2,182
|
1,249
|
1,881
|
2,324
|
|
Total Current Assets |
30,113
|
25,736
|
25,091
|
25,188
|
23,153
|
21,829
|
|
Total Non-Current Assets |
14,606
|
15,306
|
15,371
|
17,717
|
11,868
|
11,678
|
|
Intangibles |
11,102
|
11,523
|
11,973
|
14,366
|
9,276
|
9,113
|
|
Total Liabilities |
42,744
|
40,040
|
34,419
|
35,286
|
28,680
|
26,779
|
|
Total Current Liabilities |
25,750
|
24,890
|
23,824
|
23,125
|
21,014
|
18,879
|
|
Long Term Debt |
16,994
|
15,150
|
10,595
|
12,161
|
7,666
|
7,900
|
|
Shareholder equity |
1,971
|
999
|
6,043
|
7,599
|
6,323
|
6,711
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
3,403
|
2,030
|
2,044
|
1,986
|
2,218
|
2,937
|
|
Depreciation |
853
|
966
|
1,010
|
898
|
674
|
537
|
|
Cash from Investing |
453
|
-408
|
1,236
|
-6,417
|
-846
|
-4,220
|
|
Capex |
400
|
359
|
332
|
343
|
502
|
339
|
|
Cash from Financing |
-1,784
|
-2,145
|
-2,354
|
3,802
|
-1,803
|
736
|
|
Stock Issued |
0
|
-350
|
-1,000
|
-150
|
-1,251
|
-385
|
|
Debt (LT) Issued |
-1,338
|
-1,212
|
-758
|
4,646
|
-42
|
1,530
|
|
Free Cash Flow |
-695
|
-5,565
|
-275
|
5,015
|
2,750
|
1,941
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
0.9%
|
-
|
-
|
1.4%
|
1.1%
|
1.2%
|
|
NCFO / Op.Income |
492.5%
|
-
|
278.1%
|
115.7%
|
94.4%
|
126.1%
|
|
Current Ratio |
1.2
|
1.0
|
1.1
|
1.1
|
1.1
|
1.2
|
|
Financial Leverage D/E |
3.42
|
7.94
|
1.50
|
1.28
|
0.86
|
0.82
|
|
Return on Capital Avg |
7.8%
|
-46.0%
|
3.0%
|
13.2%
|
12.0%
|
12.2%
|
|
Return on Shareholder Equity |
93.1%
|
-
|
-
|
26.2%
|
20.7%
|
21.4%
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available